The management of co-morbidities in patients with heart failure
... and then in addition it importantly points pout those otherwise widely used agents which should NOT be used in the setting of HF where they would form part of any conventional hypertension guidelines for patients not having co-morbid heart failure. It therefore deserves a much closer look. ...
... and then in addition it importantly points pout those otherwise widely used agents which should NOT be used in the setting of HF where they would form part of any conventional hypertension guidelines for patients not having co-morbid heart failure. It therefore deserves a much closer look. ...
Chapter 34 Antihypertension Drugs
... The physician must establish with certainty that hypertension is persistent and requires treatment and must exclude secondary causes of hypertension that might be treated by definitive surgical procedures. ...
... The physician must establish with certainty that hypertension is persistent and requires treatment and must exclude secondary causes of hypertension that might be treated by definitive surgical procedures. ...
Cardiovascular Drugs for Pharmacology Final
... 2 agonist that↓’s CNS symp. outflow (“sympatholytic”) ...
... 2 agonist that↓’s CNS symp. outflow (“sympatholytic”) ...
351 Pharmacology 3rd sf
... Drug Receptors Receptor/Binding site “A specific protein in either the plasma membrane or interior of a target cell with which a ligand/drug combines” It must be selective in choosing ligands/drugs to bind To avoid constant activation of the receptor by promiscuous binding of many different l ...
... Drug Receptors Receptor/Binding site “A specific protein in either the plasma membrane or interior of a target cell with which a ligand/drug combines” It must be selective in choosing ligands/drugs to bind To avoid constant activation of the receptor by promiscuous binding of many different l ...
2nd Lecture 1433
... bind To avoid constant activation of the receptor by promiscuous binding of many different ligands It must change its function upon binding in such a way that the function of the biologic system (cell, tissue, etc) is altered This is necessary for the ligand to cause a pharmacologic effect ...
... bind To avoid constant activation of the receptor by promiscuous binding of many different ligands It must change its function upon binding in such a way that the function of the biologic system (cell, tissue, etc) is altered This is necessary for the ligand to cause a pharmacologic effect ...
interactions between antihypertensive agents and other drugs
... combination of i.v. verapamil and a ß-blocker, which may cause additive impairment of cardiac A-V conduction and the risk of A-V block. Another possibility is the inhibition of the therapeutic effect of a drug by an additional agent. Over-additive adverse reactions are illustrated by the following e ...
... combination of i.v. verapamil and a ß-blocker, which may cause additive impairment of cardiac A-V conduction and the risk of A-V block. Another possibility is the inhibition of the therapeutic effect of a drug by an additional agent. Over-additive adverse reactions are illustrated by the following e ...
PowerPoint Sunusu
... This decreases the number of activated receptors to below observed in the absence of the drug. They exert the opposite pharmacological effect of receptor agonists. ...
... This decreases the number of activated receptors to below observed in the absence of the drug. They exert the opposite pharmacological effect of receptor agonists. ...
ADRENERGIC RECEPTORS AS THERAPEUTIC TARGETS
... The pharmacodynamic principles that aid in the understanding of adrenergic receptors and the actions of drugs on these receptors. ...
... The pharmacodynamic principles that aid in the understanding of adrenergic receptors and the actions of drugs on these receptors. ...
Alterations in Cardiovascular Function:
... •Angiotensin I is a weak vasoconstrictor •Antiotensin II is a very powerful vasoconstrictor •Also, angiotension stimulates release of aldosterone and ADH resulting in increase blood volume (CO) ...
... •Angiotensin I is a weak vasoconstrictor •Antiotensin II is a very powerful vasoconstrictor •Also, angiotension stimulates release of aldosterone and ADH resulting in increase blood volume (CO) ...
NV and antidiarrheal drugs
... 1.CTZ stimulation (Dopamine and 5-HT): Drugs: morphine, apomorphine, digitalis, Ldopa (How? By activating the D2 receptor present richly in the CTZ), bromocriptine, estrogen, and emetine. ...
... 1.CTZ stimulation (Dopamine and 5-HT): Drugs: morphine, apomorphine, digitalis, Ldopa (How? By activating the D2 receptor present richly in the CTZ), bromocriptine, estrogen, and emetine. ...
No Slide Title - Vanderbilt University Medical Center
... • Rate control in supraventricular tachyarrhythmias • May be beneficial in hypertrophic cardiomyopathy Disadvantages • Negative inotropic effects (may unmask CHF) • Constipation (particularly with verapamil) •Significant bradycardia possible in some patients ...
... • Rate control in supraventricular tachyarrhythmias • May be beneficial in hypertrophic cardiomyopathy Disadvantages • Negative inotropic effects (may unmask CHF) • Constipation (particularly with verapamil) •Significant bradycardia possible in some patients ...
TEXT: Basic and Clinical Pharmacology by
... RATIONAL: To present current information on drugs that is important for rational drug therapy. COURSE OBJECTIVES: Students will be able to 1) Discuss drugs used in the prevention, treatment and maintenance therapy of various diseases and medical conditions. 2) Discuss effects of different classes of ...
... RATIONAL: To present current information on drugs that is important for rational drug therapy. COURSE OBJECTIVES: Students will be able to 1) Discuss drugs used in the prevention, treatment and maintenance therapy of various diseases and medical conditions. 2) Discuss effects of different classes of ...
click here to the doc
... acebutolol, have less effect on the beta2 (bronchial) receptors and are, therefore, relatively cardioselective, but they are not cardiospecific. They have a lesser effect on airways resistance but are not free of this side effect. ...
... acebutolol, have less effect on the beta2 (bronchial) receptors and are, therefore, relatively cardioselective, but they are not cardiospecific. They have a lesser effect on airways resistance but are not free of this side effect. ...
hypertension - WordPress.com
... family history of diabetes, South Asian origin). This combination can have adverse metabolic consequences which may lead to new onset diabetes. -β-Blockers do remain most suitable for younger hypertensive who have another indication for β-blockade, such as coronary heart disease, atrial fibrillation ...
... family history of diabetes, South Asian origin). This combination can have adverse metabolic consequences which may lead to new onset diabetes. -β-Blockers do remain most suitable for younger hypertensive who have another indication for β-blockade, such as coronary heart disease, atrial fibrillation ...
Newer anti anginals by Dr Ajay Nair
... Mean increase in the corrected QT interval (QTc) is approximately 6 msec, about 5% of individuals may have QTc prolongations of 15 msec or longer. (MARISA) Clinical experience in coronary syndrome population did ...
... Mean increase in the corrected QT interval (QTc) is approximately 6 msec, about 5% of individuals may have QTc prolongations of 15 msec or longer. (MARISA) Clinical experience in coronary syndrome population did ...
Jeopardy
... Flunitrazepam (Rohypnol®), this common benzo side effect hinders efforts to bring the criminal to justice ...
... Flunitrazepam (Rohypnol®), this common benzo side effect hinders efforts to bring the criminal to justice ...
Inotropes & Vasopressors
... Bronchodilatation + increased MV (small effect) Decreased cerebral BF + oxygen consumption Decreased hepatic, splanchnic + renal BF Decreased insulin secretion Administration - infusion ...
... Bronchodilatation + increased MV (small effect) Decreased cerebral BF + oxygen consumption Decreased hepatic, splanchnic + renal BF Decreased insulin secretion Administration - infusion ...
Implications
... potential all antihypertensive agents have other important mechanisms of action, indications, and side effects. • These actions may convey benefits or risks independent of BP lowering • By having a common BP goal for all treatment arms, ALLHAT aimed to evaluate the health effects of these non-BP act ...
... potential all antihypertensive agents have other important mechanisms of action, indications, and side effects. • These actions may convey benefits or risks independent of BP lowering • By having a common BP goal for all treatment arms, ALLHAT aimed to evaluate the health effects of these non-BP act ...
Chapter 11 Case Study Answer Conduct a thorough and
... for the CNS however, and the ability of 5-HT1B/1D agonists to constrict peripheral arterial vessels through their stimulation of 5-HT1D receptors in vascular smooth muscle means they are contraindicated in patients with hypertension and/or coronary artery disease. Compound 3 and its active secondary ...
... for the CNS however, and the ability of 5-HT1B/1D agonists to constrict peripheral arterial vessels through their stimulation of 5-HT1D receptors in vascular smooth muscle means they are contraindicated in patients with hypertension and/or coronary artery disease. Compound 3 and its active secondary ...
Brand Generic
... cardiac output • Initial increase in peripheral resistance from blockade of B-receptors in vessels that promote vasodilation, leaving unopposed alpha vasoconstriction ...
... cardiac output • Initial increase in peripheral resistance from blockade of B-receptors in vessels that promote vasodilation, leaving unopposed alpha vasoconstriction ...
Dr. Amani A. Noory Khartoum, Sudan
... Low Na+ conc. in tubular fluid – macula densa pathway – COX-2 and nNOS are induced – release of PGE2 and PGI2 – more renin release Baroreceptor stimulation increases sympathetic impulse – via beta-1 pathway – renin release ...
... Low Na+ conc. in tubular fluid – macula densa pathway – COX-2 and nNOS are induced – release of PGE2 and PGI2 – more renin release Baroreceptor stimulation increases sympathetic impulse – via beta-1 pathway – renin release ...
Evidence for the Existence of Nonmonotonic Dose
... YES – not limited to EDCs Key Points, Considerations and Comments: • Pharmacologically relevant “non-monotonic” concentration/response relationships exist • Examples are well accepted for both therapeutic and toxic actions of natural and synthetic compounds • “Non-monotonic” curves do not violate fu ...
... YES – not limited to EDCs Key Points, Considerations and Comments: • Pharmacologically relevant “non-monotonic” concentration/response relationships exist • Examples are well accepted for both therapeutic and toxic actions of natural and synthetic compounds • “Non-monotonic” curves do not violate fu ...